Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Price Target Cut to $3.00 by Analysts at B. Riley

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) had its price objective decreased by B. Riley from $4.00 to $3.00 in a research report sent to investors on Friday morning,Benzinga reports. B. Riley currently has a buy rating on the stock.

Several other research analysts have also commented on LCTX. Maxim Group cut their price target on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of Lineage Cell Therapeutics in a research report on Tuesday. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $2.00 price target on shares of Lineage Cell Therapeutics in a research report on Tuesday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $4.20.

Lineage Cell Therapeutics Price Performance

Shares of NYSEAMERICAN LCTX opened at $0.52 on Friday. Lineage Cell Therapeutics has a fifty-two week low of $0.48 and a fifty-two week high of $1.61. The firm has a market cap of $114.62 million, a price-to-earnings ratio of -4.33 and a beta of 1.21. The stock’s 50-day simple moving average is $0.60.

Institutional Trading of Lineage Cell Therapeutics

Institutional investors have recently bought and sold shares of the company. Fort Sheridan Advisors LLC raised its holdings in shares of Lineage Cell Therapeutics by 71.5% in the fourth quarter. Fort Sheridan Advisors LLC now owns 55,177 shares of the company’s stock worth $28,000 after acquiring an additional 23,000 shares during the last quarter. Atria Wealth Solutions Inc. acquired a new position in shares of Lineage Cell Therapeutics in the fourth quarter worth $29,000. HighTower Advisors LLC raised its holdings in shares of Lineage Cell Therapeutics by 49.5% in the fourth quarter. HighTower Advisors LLC now owns 57,706 shares of the company’s stock worth $29,000 after acquiring an additional 19,100 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of Lineage Cell Therapeutics by 35.5% in the fourth quarter. SG Americas Securities LLC now owns 68,973 shares of the company’s stock worth $35,000 after acquiring an additional 18,053 shares during the last quarter. Finally, Two Sigma Advisers LP raised its holdings in shares of Lineage Cell Therapeutics by 312.2% in the fourth quarter. Two Sigma Advisers LP now owns 86,964 shares of the company’s stock worth $44,000 after acquiring an additional 65,864 shares during the last quarter. 62.47% of the stock is currently owned by hedge funds and other institutional investors.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.